HUBS:NYSEHubSpot, Inc. Analysis
Data as of 2026-03-13 - not real-time
$260.65
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
HubSpot delivered a robust fourth‑quarter, with revenue climbing 20.4% year‑on‑year to $846.7 million and adjusted earnings per share of $3.09 beating consensus estimates, while billings—a leading indicator of future revenue—also accelerated. At $260.65 per share, the stock trades well below the DCF‑derived fair value of $418, implying roughly a 44% upside potential and a forward P/E of 17 versus a trailing P/E of 307, highlighting the market’s current pricing disconnect. Technical indicators show the price hovering just above the 20‑day SMA (259) but beneath the 50‑day (290) and 200‑day (430) averages, a bearish trend reinforced by decreasing volume and an 83% 30‑day volatility. The MACD histogram is positive, suggesting short‑term momentum, while the RSI sits at a neutral 46. Support rests around $214 and resistance near $297. Analyst sentiment is strongly positive, with 34 analysts rating the stock a “strong buy” and a median price target of $350. Despite the high trailing P/E relative to the industry, the company’s solid cash position ($1.7 billion), low debt ($262 million), and strong operating cash flow underpin its growth narrative, though elevated volatility, beta (1.33) and a bearish macro backdrop inject notable risk.
Given the blend of strong earnings momentum, attractive valuation upside from DCF, and growth‑oriented fundamentals, HubSpot presents a compelling case for investors willing to navigate its price volatility and execution risks tied to AI initiatives and market sentiment.
Given the blend of strong earnings momentum, attractive valuation upside from DCF, and growth‑oriented fundamentals, HubSpot presents a compelling case for investors willing to navigate its price volatility and execution risks tied to AI initiatives and market sentiment.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Positive MACD histogram indicating near‑term momentum
- Revenue beat and strong billings suggest continued demand
- Price near support with upside potential to $297
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value implies ~44% upside
- Forward P/E of 17 aligns with growth expectations
- Robust cash balance and low leverage support expansion
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- AI‑driven product roadmap could drive sustainable growth
- High volatility and beta increase market risk
- Elevated trailing P/E and lack of dividend may limit valuation appeal
Key Metrics & Analysis
Financial Health
Revenue Growth20.40%
Profit Margin1.47%
P/E Ratio306.6
ROE2.31%
ROA0.20%
Debt/Equity12.70
P/B Ratio6.6
Op. Cash Flow$760.7M
Free Cash Flow$651.6M
Industry P/E33.6
Technical Analysis
TrendBearish
RSI46.3
Support$214.13
Resistance$297.00
MA 20$259.10
MA 50$289.99
MA 200$429.78
MACDBullish
VolumeDecreasing
Fear & Greed Index72.43
Valuation
Fair Value$418.26
Target Price$375.19
Upside/Downside43.95%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta1.33
Volatility83.08%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.